| Project/Area Number |
15K21156
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
Nishimura Yuya 神戸大学, 科学技術イノベーション研究科, 特命助教 (40728218)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | ドラッグデリバリーシステム / バイオナノカプセル / 抗癌剤ドキソルビシン / 放射線増感剤 / ナノ粒子 / 放射線治療 / Affibody / in vivo / 無機ナノ粒子 |
|---|
| Outline of Final Research Achievements |
We have developed bio-nanocapsule derived from hepatitis B virus as a carrier for drug delivery system and achieved some progress in vitro. Therefore, to apply this carrier in a clinical application, we demonstrated availability in vivo. As the result, delivery of anticancer drug (doxorubicin) showed antitumor effect in mouse xenograft models. Next, we measured time course of biodistribution of PAATiOx with radiosensitization efficacy and showed accumulation within the tumor. Then, in combination with X-irradiation, antitumor effect was observed. Therefore, we indicated that this carrier is available in vivo.
|
